Protocols›Metabolic & fat loss›Belly Fat — Summer Cut
← Protocols
POM · prescription medicinesRCT-backed · parts, not combinationSpot reduction is not real

Belly Fat — Summer Cut

Stack: Tesamorelin + Semaglutide + AOD-9604 · abdominal / visceral fat
"The honest version of a summer cut. Tesamorelin is the only one here with belly-specific (visceral-fat) trial data; a GLP-1 drives real systemic loss; AOD-9604 is the hyped fat-burner that failed its obesity trials. You cannot spot-reduce belly fat by injecting it — fat loss is systemic."
GoalAbdominal / visceral fat
Compounds3 · Tesamorelin + Semaglutide + AOD-9604
Humans exposed (est.)High (Tesamorelin, Semaglutide — approved drugs)
StatusUK: Tesamorelin & Semaglutide are prescription-only medicines (POM, .uk-pom) — buying/supplying without a prescription is an offence · AOD-9604: research material · Combination is not an approved therapy
In this stack — snapshot; tap through for the full molecule file
Provenance & evidence layers — of the combination, not the parts
Evidenced — but for visceral fat
What has data
Tesamorelin (a GHRH analog, FDA-approved as Egrifta) has randomised-trial evidence for reducing visceral abdominal fat. Semaglutide has large RCTs for systemic weight loss.
What it means for belly fat
Tesamorelin lowers deep abdominal fat via the GH axis — a systemic effect, not because it is injected near the belly.
Evidence it adds
Genuine human efficacy for the individual drugs.
Basis: approved drugs with RCT evidence (Tesamorelin, Semaglutide)
Spot reduction is not real
The myth
Injecting a “fat-burner” into the belly does not preferentially burn belly fat. Fat is mobilised systemically through energy balance — local injection site does not direct where fat is lost.
AOD-9604
The marketed lipolytic GH-fragment failed its Phase 2 obesity trials — no better than placebo for weight loss. Included here only because community stacks use it; the evidence does not support it.
Basis: physiology + failed AOD-9604 obesity trials — myth shown, not sold
Regulatory — read carefully
UK (MHRA)
Tesamorelin and Semaglutide are prescription-only medicines. Supplying or buying them without a prescription is unlawful in the UK.
AOD-9604
Sold as a research chemical — not a licensed medicine.
What it means
This is the AMBER tier — POMs are involved. The legal route to Tesamorelin/Semaglutide is a clinician and a pharmacy.
Why it matters
Grey-market GLP-1/GHRH carry dosing, purity and counterfeit risks on top of the legal exposure.
Basis: UK POM status (Tesamorelin, Semaglutide)
Why this combination

The honest hierarchy: Tesamorelin is the only compound here with trial evidence aimed at abdominal (visceral) fat specifically. Semaglutide produces large, real systemic weight loss — belly fat falls as part of overall loss, not selectively. AOD-9604 is the hyped “lipolytic” that did not beat placebo in obesity trials. There is no peptide that melts belly fat on its own, and none that spot-reduces. Diet, training and overall energy balance remain the engine; these are adjuncts at best. Free information is full; actionable depth is gated.

Members only · the actionable depth
See exactly how it's run
Doses, cycle structure and what to monitor are part of membership. The provenance, evidence and exposure above are always free.
Get TiQ1 · Free →
Free · just create an account
Cycle shape — how it's typically structured, not a schedule to follow
Loading
build up
Maintenance
hold / taper
Off
stop / reassess
Convention from community use, not a prescription.
What's worth monitoring

If a clinician is involved, the GH axis and metabolic markers are the ones that matter here: fasting glucose and HbA1c (GHRH analogs can nudge insulin resistance), IGF-1, and standard lipids/blood pressure. GLP-1 use brings its own GI tolerance and, rarely, pancreatitis considerations. None of this is a green light — it is what a careful clinician would track. General information, not medical advice.

Combination evidence
Visceral-fat efficacy Strong (Tesamorelin)

RCT evidence for reducing deep abdominal fat — systemically, via the GH axis.

AOD-9604 None

Failed Phase 2 obesity trials — no better than placebo.

The honest ceiling

No peptide spot-reduces belly fat. Energy balance is the engine; these are adjuncts, two of them prescription-only.

Fast facts
Compounds

Tesamorelin · Semaglutide · AOD-9604

Humans exposed (est.)

High (Tesamorelin, Semaglutide — approved).

UK strip

AMBER — contains POMs (Tesamorelin, Semaglutide)